Company intelligence / Profile preview

e4life

Milan, Lombardy, Italy

Ownership: Private
Development stage: Other

Overview

e4life's e4shield-based devices demonstrated over 90% efficacy in inactivating airborne viral particles (COVID-19, influenza, RSV, avian, and swine flu) in validated, peer-reviewed and independent laboratory tests. Devices are certified as safe for use around humans and animals and marketed for both personal wearable and ambient room use.[2][3][5]

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

ELT Group (joint venture partner)Lendlease (joint venture partner)Celio Military Hospital (clinical validation)ViroStatics (independent research validation)University of Milan Department of Biomedical and Clinical Sciences (tests and validation)

Beyond the preview

Go deeper on e4life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on e4life.

Explore the full profile